# Quantum Biopharma Ltd.: Form 20-F for the period ended Dec 31, 2022

- Company: [Quantum Biopharma Ltd.](/companies/qntm.md) (CIK 1771885)
- Form: 20-F
- Filed: 2023-03-31
- Accepted by EDGAR: Mar 31, 2023, 21:18 ET
- Period: 2022-12-31
- Accession: 0001062993-23-008232
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1771885/000106299323008232/form20f.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1771885/000106299323008232/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2022-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating income | 12 months, 2022-01-01 to 2022-12-31 | −$27.4m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months, 2022-01-01 to 2022-12-31 | −$23.6m | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months, 2022-01-01 to 2022-12-31 | −$28.3m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2022-01-01 to 2022-12-31 | $114.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2022-12-31 | $17.0m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2022-12-31 | $17.9m | ifrs-full:CurrentAssets |
| Total assets | at 2022-12-31 | $38.4m | ifrs-full:Assets |
| Current liabilities | at 2022-12-31 | $7.8m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2022-12-31 | $7.9m | ifrs-full:Liabilities |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1771885/000106299323008232/form20f.htm

Filed Mar 31, 2023.
Source: SEC EDGAR, the filing index for accession 0001062993-23-008232. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.